ATE110572T1 - Verwendung eines detektierbaren, markierten, immunoglobulins oder eines fragmentes davon zur herstellung eines mittels für den nachweis eines entzündungsherdes in vivo. - Google Patents

Verwendung eines detektierbaren, markierten, immunoglobulins oder eines fragmentes davon zur herstellung eines mittels für den nachweis eines entzündungsherdes in vivo.

Info

Publication number
ATE110572T1
ATE110572T1 AT87300395T AT87300395T ATE110572T1 AT E110572 T1 ATE110572 T1 AT E110572T1 AT 87300395 T AT87300395 T AT 87300395T AT 87300395 T AT87300395 T AT 87300395T AT E110572 T1 ATE110572 T1 AT E110572T1
Authority
AT
Austria
Prior art keywords
fragment
detecting
agent
preparation
vivo
Prior art date
Application number
AT87300395T
Other languages
English (en)
Inventor
Robert H Rubin
William H Strauss
Original Assignee
Gen Hospital Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gen Hospital Corp filed Critical Gen Hospital Corp
Application granted granted Critical
Publication of ATE110572T1 publication Critical patent/ATE110572T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817—Toxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/14—Peptides, e.g. proteins
    • A61K49/16—Antibodies; Immunoglobulins; Fragments thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1018—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2123/00—Preparations for testing in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Genetics & Genomics (AREA)
  • Pain & Pain Management (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Toxicology (AREA)
  • Rheumatology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • External Artificial Organs (AREA)
  • Chemical Treatment Of Metals (AREA)
AT87300395T 1986-01-16 1987-01-16 Verwendung eines detektierbaren, markierten, immunoglobulins oder eines fragmentes davon zur herstellung eines mittels für den nachweis eines entzündungsherdes in vivo. ATE110572T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US81958586A 1986-01-16 1986-01-16
PCT/US1987/000079 WO1987004351A1 (en) 1986-01-16 1987-01-12 Method for the diagnosis and treatment of inflammation

Publications (1)

Publication Number Publication Date
ATE110572T1 true ATE110572T1 (de) 1994-09-15

Family

ID=25228549

Family Applications (2)

Application Number Title Priority Date Filing Date
AT87300395T ATE110572T1 (de) 1986-01-16 1987-01-16 Verwendung eines detektierbaren, markierten, immunoglobulins oder eines fragmentes davon zur herstellung eines mittels für den nachweis eines entzündungsherdes in vivo.
AT93202324T ATE283710T1 (de) 1986-01-16 1987-01-16 Diagnose und behandlung von entzündung

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT93202324T ATE283710T1 (de) 1986-01-16 1987-01-16 Diagnose und behandlung von entzündung

Country Status (9)

Country Link
EP (2) EP0577225B9 (de)
JP (1) JP2515357B2 (de)
AT (2) ATE110572T1 (de)
AU (1) AU597032B2 (de)
CA (1) CA1288688C (de)
DE (3) DE3750434T3 (de)
ES (2) ES2056812T5 (de)
GR (1) GR940300027T1 (de)
WO (1) WO1987004351A1 (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU597032B2 (en) * 1986-01-16 1990-05-24 General Hospital Corporation, The Method for the diagnosis and treatment of inflammation
FR2639231A1 (fr) * 1988-11-23 1990-05-25 Merieux Inst Utilisation de fragments fc d'immunoglobulines g humaines, de peptides analogues du fragment fc, ou d'immunoglobulines g humaines dans l'obtention d'un medicament preparatoire a l'administration chez l'homme, dans un but therapeutique ou de diagnostic, d'anticorps monoclonaux
US5792444A (en) * 1989-05-09 1998-08-11 The General Hospital Corporation Labeled chemotactic peptides to image focal sites of infection or inflammation
NZ314680A (en) * 1989-05-09 2000-08-25 Ortho Pharma Corp Treating localised infection or inflammation with a therapeutically conjugated chemotactic peptide
EP0485664A1 (de) * 1990-11-13 1992-05-20 Mallinckrodt Diagnostica (Holland) B.V. Verfahren zur Herstellung von einem diagnostischen Mittel zur Feststellung von Entzündungen
DE69416078T2 (de) * 1993-10-22 1999-05-27 Nihon Mediphysics Co Ltd Peptide mit Affinität für Entzündungen und deren radiomarkierte, diagnostische Zusammensetzungen
DE19514088A1 (de) * 1995-04-13 1996-10-17 Deutsches Krebsforsch Konjugat zur Behandlung von Entzünduns-, Infektions- und/oder Hauterkrankungen

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2004464B (en) * 1977-06-30 1982-01-13 Cehovic G Method of testing inflammation
US4315906A (en) * 1979-05-21 1982-02-16 New England Nuclear Corporation Cold insoluble globulin, its purification and use
US4472371A (en) * 1979-10-29 1984-09-18 Summa Medical Corporation Radiolabeled antibody to anti-tumor associated antigen and process
US4444744A (en) * 1980-03-03 1984-04-24 Goldenberg Milton David Tumor localization and therapy with labeled antibodies to cell surface antigens
GB2101407A (en) * 1981-05-14 1983-01-12 Bulpitt And Sons Limited Automatic electric kettle
US4522918A (en) * 1981-12-15 1985-06-11 Jeffery Schlom Process for producing monoclonal antibodies reactive with human breast cancer
US4472509A (en) * 1982-06-07 1984-09-18 Gansow Otto A Metal chelate conjugated monoclonal antibodies
US4732864A (en) * 1983-10-06 1988-03-22 E. I. Du Pont De Nemours And Company Trace-labeled conjugates of metallothionein and target-seeking biologically active molecules
GR850552B (de) * 1984-03-07 1985-07-05 Du Pont
US4636380A (en) * 1984-04-23 1987-01-13 Wong Dennis W Novel physiologic chemical method of labeling protein substances with the radionuclides of indium
US4634586A (en) * 1984-05-21 1987-01-06 The Board Of Trustees Of The Leland Stanford Junior University Reagent and method for radioimaging leukocytes
US4659839A (en) * 1984-10-10 1987-04-21 Mallinckrodt, Inc. Coupling agents for radiolabeled antibody fragments
US4639365A (en) * 1984-10-18 1987-01-27 The Board Of Regents, The University Of Texas System Gadolinium chelates as NMR contrast agents
GB8426470D0 (en) * 1984-10-19 1984-11-28 Technology Licence Co Ltd Monoclonal antibodies
AU597877B2 (en) * 1984-12-26 1990-06-14 Teijin Limited Anti-pseudomonas aeruginosa human monoclonal antibody
AU597032B2 (en) * 1986-01-16 1990-05-24 General Hospital Corporation, The Method for the diagnosis and treatment of inflammation
GB8610202D0 (en) * 1986-04-25 1986-05-29 Technology Licence Co Ltd Monoclonal antibodies
GB8621910D0 (en) * 1986-09-11 1986-10-15 Technology Licence Co Ltd Monoclonal antibodies

Also Published As

Publication number Publication date
EP0241106B1 (de) 1994-08-31
DE3750434D1 (de) 1994-10-06
GR940300027T1 (en) 1994-05-31
DE3750434T2 (de) 1995-03-23
ES2056812T5 (es) 1998-11-16
DE3752380D1 (de) 2005-01-05
JPS63502280A (ja) 1988-09-01
EP0241106B2 (de) 1998-07-08
WO1987004351A1 (en) 1987-07-30
EP0577225B9 (de) 2005-03-02
EP0577225B1 (de) 2004-12-01
EP0241106A3 (en) 1989-02-08
DE3752380T2 (de) 2005-11-03
EP0241106A2 (de) 1987-10-14
ES2053403T3 (es) 2005-06-01
EP0577225A1 (de) 1994-01-05
ES2053403T1 (es) 1994-08-01
DE577225T1 (de) 1994-09-22
JP2515357B2 (ja) 1996-07-10
AU597032B2 (en) 1990-05-24
ATE283710T1 (de) 2004-12-15
CA1288688C (en) 1991-09-10
ES2056812T3 (es) 1994-10-16
AU6937787A (en) 1987-08-14
DE3750434T3 (de) 1999-04-08

Similar Documents

Publication Publication Date Title
ATE115588T1 (de) Ein verfahren zur herstellung eines antikörpers, der zur bestimmung der anwesenheit eines menschlichen oncogens befähigt ist.
DE68927459D1 (de) Nachweis einer neurologischen Krankheit oder einer Funktionsstörung
ES513992A0 (es) "un metodo para detectar sangre humana oculta en muestras de deposicion humana".
DE3587811D1 (de) Befehlsvorausholeinrichtung mit Vorhersage der Verzweigungsbestimmung für jeden Verzweigungszählbefehl.
ES2132272T3 (es) Procedimiento para la determinacion de aductos de hemoglobina.
IT1152386B (it) Catetere per la misurazione della pressione dell'uretra
ATE110572T1 (de) Verwendung eines detektierbaren, markierten, immunoglobulins oder eines fragmentes davon zur herstellung eines mittels für den nachweis eines entzündungsherdes in vivo.
SE8400587D0 (sv) Sett att bestemma isotransferriner
ATE329265T1 (de) Verfahren zur instrumentellen bestimmung einer sich zeitabhängig ändernden messgrösse
DE68911653T2 (de) Antagonist für Interleukin-5 zur Verhütung oder Verminderung von Eosinophilie.
DE3587542T2 (de) Verfahren zur Diagnose in vitro von menschlichen Cytomegalovirusinfektionen und Anwendung von monoklonalen Antikörpern gegen Cytomegaloviren, die mit einer cytomegalovirusinduzierten Proteinkinase reagieren.
DE3684223D1 (de) Monoklonale antikoerper.
DE3679763D1 (de) Verfahren und zusammensetzungen zur bestimmung von heparin.
EP0621480A3 (de) Diagnose und Überwachung von Patienten mit Lungenkrebs durch Messung von NCA 50/90 im Blut.
EP0628820A3 (de) Diagnose und Überwachung von Patienten mit Dickdarmkrebs durch Messung von NCA 50/90 im Blut.
ES554615A0 (es) Un procedimiento para medir la concentracion de digitoxina
DE69019431T2 (de) Verwendung von 15-Keto-Prostansäure-Derivaten zur Herstellung eines Medikaments für die Verbesserung der Ausscheidung des Kaliumions.
FI963671A0 (fi) Väline autoimmuunisairauksien hoitamiseksi ja menetelmä niiden hoitamiseksi
ATE84069T1 (de) Murin-hybridoma lym-2 und diagnostikantikoerper, der dadurch hergestellt ist.
DE122478T1 (de) Verfahren zur herstellung eines monoklonalen antikoerpers mit spezifizitaet fuer vernetzte fibrinderivate und ein testverfahren mittels dieses antikoerpers.
ATE90793T1 (de) Antikoerper, verfahren zu ihrer herstellung, klone zur erzeugung der antikoerper sowie verwendung der antikoerper zur diagnose und therapie von tumoren.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee